Printer Friendly

FDA approves bone marrow product to treat immune-related low platelet counts.

The US Food and Drug Administration (FDA) has approved a bone marrow product developed to treat immune-related low platelet counts. Nplate (romiplostim) is the first bone marrow stimulator to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.

The condition, which usually develops in adults, is known as chronic immune thrombocytopenic purpura (ITP), a disease that results in a low number of platelets, the blood components that help with clotting. In patients with chronic ITP, the immune system is believed to destroy platelets and the patient's bone marrow is often unable to compensate for the loss.

The estimated 140,000 people with chronic ITP are prone to bruising and at risk for life-threatening bleeding. Current medical treatment includes corticosteroids and immunoglobulin. Surgery to remove the spleen, a procedure known as a splenectomy, may help some patients. Nplate is approved only for patients with chronic ITP who do not respond sufficiently to current treatments.

The FDA said it based its approval on two randomized clinical trials of about 125 patients who received at least one prior ITP treatment. One study enrolled patients who still had their spleen, the other enrolled patients who did not.

During six months of treatment, patients who received Nplate had significantly higher platelet counts and maintained those higher counts compared to those who did not receive the drug. The response to Nplate was higher in those patients who still had their spleen than in those patients who had undergone a splenectomy. In those patients who did not receive Nplate, only one experienced a sustained increase in platelet counts.

Safety concerns with Nplate include fibrous deposits in the bone marrow and the possibility that once Nplate is stopped, platelet counts could drop below they were before beginning the treatment.

The FDA said a Risk Evaluation and Mitigation Strategy (REMS) has developed to address the risks of Nplate therapy. Under the Food and Drug Administration Amendments Act of 2007, the agency has determined that a REMS is necessary for the benefits of Nplate to outweigh the risks of the product. The REMS will include a Medication Guide for patients and requires that all prescribers and patients enroll in a special program to track the long term safety of Nplate therapy.
COPYRIGHT 2008 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:Nov 1, 2008
Words:378
Previous Article:Hospital patients with CKD are higher risk for adverse events than patients without the disease, study finds.
Next Article:Commentary - One-year moratorium on implementation of HHS OPTN regulation - who won, who lost may prove to be deceptive.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |